Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab Induction and Maintenance in Plaque Psoriasis
NCT02786732Phase 3Terminated
- Sponsor
- MedDerm Associates
- Start
- Aug 2012
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brodalumab in plaque psoriasis (4 arms), sponsored by MedDerm Associates. Primary endpoint: Psoriasis Area and Severity Index Improvement at 12 weeks. Started Aug 2012; status: terminated.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02786732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786732.